利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.015 秒)

    Defective influenza virus particles
    3.
    发明公开
    Defective influenza virus particles 审中-公开
    Defekte Partikeln des流感病毒

    公开(公告)号：EP2272950A2

    公开(公告)日：2011-01-12

    申请号：EP10182312.8

    申请日：2005-11-08

    申请人： Abbott Biologicals B.V. ,  Erasmus University Medical Center Rotterdam

    发明人： de Wit, Emmie ,  Spronken, Monique I.J. ,  Fouchier, Ron A.M. ,  Osterhaus, Albert D.M.E.

    IPC分类号： C12N7/04 ,  C12N5/10 ,  A61K39/145 ,  A61K48/00

    CPC分类号： C12N7/00 ,  A61K48/00 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/5258 ,  C07K14/005 ,  C12N15/86 ,  C12N2760/16122 ,  C12N2760/16143 ,  C12N2760/16152 ,  C12N2760/16162

    摘要： The invention relates to the field of influenza virus and the vaccination against flu. The invention provides a conditionally defective influenza virus particle having seven different influenza nucleic acid segments. The invention also provides a conditionally defective influenza virus particle lacking an influenza nucleic acid segment selected from the group of segments essentially encoding acidic polymerase (PA), the basic polymerase 1 (PB1) and the basic polymerase 2 (PB2). In particular, the invention provides defective influenza virus particles having seven different influenza nucleic acid segments and lacking an influenza nucleic acid segment essentially encoding acidic polymerase. Furthermore, the invention provides use of a composition comprising a defective influenza virus particle according to the invention for the production of a pharmaceutical composition directed at generating immunological protection against infection of a subject with an influenza virus, and provides a method for generating immunological protection against infection of a subject with an influenza virus comprising providing a subject in need thereof with a composition comprising such defective influenza virus particle.

    摘要翻译： 本发明涉及流感病毒领域和针对流感的疫苗。 本发明提供了具有七种不同流感核酸片段的有条件缺陷型流感病毒颗粒。 本发明还提供了缺乏流感核酸片段的条件缺陷型流感病毒颗粒，其选自基本上编码酸性聚合酶（PA），碱性聚合酶1（PB1）和碱性聚合酶2（PB2）的片段组。 特别地，本发明提供了具有七种不同流感核酸片段并且缺乏基本上编码酸性聚合酶的流感核酸片段的有缺陷的流感病毒颗粒。 此外，本发明提供了包含根据本发明的有缺陷的流感病毒颗粒的组合物用于生产药物组合物的用途，所述药物组合物旨在产生针对流感病毒感染受试者的免疫保护，并且提供了用于产生免疫保护的方法 感染具有流感病毒的受试者包括用包含这种有缺陷的流感病毒颗粒的组合物提供有需要的受试者。

    Adjuvant testing for vaccine preparations
    4.
    发明公开
    Adjuvant testing for vaccine preparations 审中-公开
    HilfsstoffprüfungfürImpfstoffzubereitungen

    公开(公告)号：EP2207031A1

    公开(公告)日：2010-07-14

    申请号：EP09160509.7

    申请日：2009-05-18

    申请人： Abbott Biologicals B.V.

    发明人： Breedveld, Pauline ,  de Gruijl, Tanja ,  van de Ven, Rieneke ,  Scheper, Riekeld J.

    IPC分类号： G01N33/50 ,  C12N5/07

    CPC分类号： G01N33/5088 ,  C12N2503/06

    摘要： The present invention belongs to the field of pharmaceutical industry and relates to a method for testing an exogenous adjuvant in an ex vivo skin model, comprising the following steps:
    a) providing an ex vivo skin tissue,
    b) applying said exogenous adjuvant to be tested to the skin tissue, and
    c) determining the immunological status of cells from the skin tissue.
    Furthermore, it relates to the use of the method according to the invention for the development of a vaccine preparation and to the use of an exogenous adjuvant selected by the method according to the invention for a vaccine preparation.
    Moreover, the present invention relates to the use of an exogenous adjuvant.

    摘要翻译： 本发明属于制药工业领域，涉及一种在离体皮肤模型中测试外源性佐剂的方法，包括以下步骤：a）提供离体皮肤组织，b）施用待测试的外源性佐剂 皮肤组织，和c）确定细胞从皮肤组织的免疫状态。 此外，本发明涉及根据本发明的方法用于开发疫苗制剂的用途，以及通过根据本发明的方法选择的用于疫苗制剂的外源性佐剂的应用。 此外，本发明涉及外源性佐剂的用途。

    PROCESS FOR PRODUCING VIRAL ANTIGEN AND VACCINES
    5.
    发明公开
    PROCESS FOR PRODUCING VIRAL ANTIGEN AND VACCINES 有权
    VERFAHREN ZUR HERSTELLUNG VON ORTHOMYXOVIRALEM ANTIGEN UND IMPFSTOFFEN

    公开(公告)号：EP2734619A1

    公开(公告)日：2014-05-28

    申请号：EP12734892.8

    申请日：2012-07-04

    申请人： Abbott Biologicals B.V.

    发明人： CUI, Yi-Qing ,  WANG, Yiding ,  THUS, Jo ,  VAN 'T HOF, Ron ,  SHAKER, Sabah ,  VAN ROOIJ, Geertje Jacoba

    IPC分类号： C12N7/02

    CPC分类号： C12N7/00 ,  C12N2760/16151

    摘要： The present invention belongs to the field of pharmaceutical industry and relates to a method for the production of viral antigen derived from enveloped virus, comprising the steps of providing a fluid comprising enveloped virus, clarifying the fluid comprising said enveloped virus, reducing the volume of the obtained liquid harvest, solubilizing the enveloped virus, and purifying viral antigen. The present invention further refers to the use of said method for the production of a vaccine preparation.

    摘要翻译： 本发明属于制药工业领域，涉及生产包膜病毒的病毒抗原的方法，包括以下步骤：提供包含包膜病毒的流体，澄清包含所述包膜病毒的流体，减少 获得液体收获物，溶解包膜病毒，并纯化病毒抗原。 本发明还涉及所述用于制备疫苗制剂的方法的用途。

    EXTRANEOUS AGENTS TESTING
    10.
    发明公开
    EXTRANEOUS AGENTS TESTING 有权
    测试异物

    公开(公告)号：EP2435074A1

    公开(公告)日：2012-04-04

    申请号：EP10724012.9

    申请日：2010-05-26

    申请人： Abbott Biologicals B.V.

    发明人： SCHOEN, Pieter Joseph ,  KERSTEN, Alexander Jeroen ,  MEDEMA, Jeroen Kristiaan ,  THUS, Johannes Lambertus Gerardus

    IPC分类号： A61K39/12 ,  A61K39/145 ,  C07K14/11 ,  G01N33/53

    CPC分类号： A61K39/145 ,  A61K39/12 ,  A61K2039/53 ,  C12N2760/16134 ,  G01N33/53 ,  G01N2500/04

    摘要： The present invention belongs to the field of pharmaceutical industry and specifies a method for testing extraneous agents in a composition comprising at least one active agent, comprising the steps of: a) contacting an antibody, which had been raised against an expression product of a polynucleotide construct comprising a sequence encoding at least a part of the active agent, with the composition comprising at least one active agent, wherein the antibody binds to the active agent, and b) determining the presence or absence of extraneous agents in the composition subsequent to step a). Furthermore, the invention specifies a process for producing a pharmaceutical composition by carrying out said method, to the use of a polynucleotide construct for testing the presence or absence of the active agent or of any extraneous or infectious agent in a composition to be tested. The present invention also relates to particular polynucleotides and polynucleotide constructs as useful substances in the field of influenza vaccines, as well as non-human organisms, transgenic animals or microorganisms containing the polynucleotides and/or polynucleotide constructs. The present invention is also directed to kit of parts.